Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical ...
Sept 24 (Reuters) - City Therapeutics filed for a US initial public offering on Thursday, joining a rush of biotech firms ...
Investor's Business Daily on MSN
The biggest losers in biotech — and it had nothing to do with 'compelling,' 'best-in-disease' data
Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
Immunovant shares were on track for their worst session in over a year after the biotech said it was halting development of ...
Aurion Biotech, Inc. ("Aurion Biotech"), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced ...
As Chinese companies push beyond “me-too” drugs and the country lays out a new five-year plan targeting a $522 billion–strong ...
1d
Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung ...
AI continued to attract fresh venture capital this week, but the money was spread across very different parts of the ...
Meroueh may have found a way to clean up steelmaking without driving up the price. Her new furnace turns iron ore into ...
AJ Scaramucci's Solari Capital exits stealth with $350M deployed across AI, biotech, Bitcoin mining, and DeFi under a programmable reality ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results